| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jason Wilson, Travis Simpson, Kevin Spelma. Total cannabidiol (CBD) concentrations and yields from traditional extraction methods: Percolation vs. maceration. Frontiers in pharmacology. vol 13. 2022-11-10. PMID:36353485. |
this is especially the case when it comes to cannabinoids from cannabis. |
2022-11-10 |
2023-08-14 |
Not clear |
| Farhang Modaresi, Kaivan Talachia. The Characteristics of Clinical Trials on Cannabis and Cannabinoids: A Review of Trials for Therapeutic or Drug Development Purposes. Pharmaceutical medicine. 2022-11-10. PMID:36357543. |
the characteristics of clinical trials on cannabis and cannabinoids: a review of trials for therapeutic or drug development purposes. |
2022-11-10 |
2023-08-14 |
Not clear |
| Farhang Modaresi, Kaivan Talachia. The Characteristics of Clinical Trials on Cannabis and Cannabinoids: A Review of Trials for Therapeutic or Drug Development Purposes. Pharmaceutical medicine. 2022-11-10. PMID:36357543. |
patients and healthcare practitioners are increasingly interested in using cannabis and cannabinoids to address unmet clinical needs. |
2022-11-10 |
2023-08-14 |
Not clear |
| Farhang Modaresi, Kaivan Talachia. The Characteristics of Clinical Trials on Cannabis and Cannabinoids: A Review of Trials for Therapeutic or Drug Development Purposes. Pharmaceutical medicine. 2022-11-10. PMID:36357543. |
we have reviewed the registered clinical trials on cannabis and cannabinoids for therapeutic or drug development purposes to underline the past and current attempts to generate robust clinical evidence and identify existing knowledge gaps. |
2022-11-10 |
2023-08-14 |
Not clear |
| Benedikt Pulver, Svenja Fischmann, Ana Gallegos, Rachel Christi. EMCDDA framework and practical guidance for naming synthetic cannabinoids. Drug testing and analysis. 2022-11-08. PMID:36346325. |
synthetic cannabinoids (scs), often sold as 'legal' replacements for cannabis, are the largest group of new psychoactive substances monitored by the european monitoring centre for drugs and drug addiction (emcdda). |
2022-11-08 |
2023-08-14 |
Not clear |
| Mario Barbieri, Micaela Tirri, Sabrine Bilel, Raffaella Arfè, Giorgia Corli, Beatrice Marchetti, Lorenzo Caruso, Marie Soukupova, Virginia Cristofori, Giovanni Serpelloni, Matteo Mart. Synthetic cannabinoid JWH-073 alters both acute behavior and Frontiers in psychiatry. vol 13. 2022-11-07. PMID:36339851. |
synthetic cannabinoid jwh-073 alters both acute behavior and jwh-073 is a synthetic cannabinoid (scb) that is illegally marketed within an "herbal blend", causing psychoactive effects more intense than those produced by cannabis. |
2022-11-07 |
2023-08-14 |
Not clear |
| Hollis C Karoly, Mark A Prince, Noah N Emery, Emma E Smith, Cianna J Piercey, Bradley T Conne. Protocol for a mobile laboratory study of co-administration of cannabis concentrates with a standard alcohol dose in humans. PloS one. vol 17. issue 11. 2022-11-03. PMID:36327298. |
two important variables that may influence the effects of cannabis and alcohol are cannabinoid content (i.e., the ratio of cannabidiol [cbd] and 9-tetrahydrocannabinol [thc]) as well as the order of use (i.e., cannabis before alcohol vs. alcohol before cannabis). |
2022-11-03 |
2023-08-14 |
human |
| Hollis C Karoly, Mark A Prince, Noah N Emery, Emma E Smith, Cianna J Piercey, Bradley T Conne. Protocol for a mobile laboratory study of co-administration of cannabis concentrates with a standard alcohol dose in humans. PloS one. vol 17. issue 11. 2022-11-03. PMID:36327298. |
thus, there is a need for experimental co-use studies exploring the impact of cannabinoid content (particularly of highly potent cannabis concentrates) and order effects on intoxication. |
2022-11-03 |
2023-08-14 |
human |
| H Yavuz Inc. Cannabis and Cannabinoids in Psychiatry: Risks and Benefits. The American journal of psychiatry. vol 179. issue 11. 2022-11-01. PMID:36317333. |
cannabis and cannabinoids in psychiatry: risks and benefits. |
2022-11-01 |
2023-08-14 |
Not clear |
| Hakan Kayir, Jessica Ruffolo, Patrick McCunn, Jibran Y Khokha. The Relationship Between Cannabis, Cognition, and Schizophrenia: It's Complicated. Current topics in behavioral neurosciences. 2022-11-01. PMID:36318403. |
secondly, chronic cannabis use may alter endocannabinoid signaling in the brain which could be a protective factor for developing psychosis or cognitive impairments. |
2022-11-01 |
2023-08-14 |
human |
| Hakan Kayir, Jessica Ruffolo, Patrick McCunn, Jibran Y Khokha. The Relationship Between Cannabis, Cognition, and Schizophrenia: It's Complicated. Current topics in behavioral neurosciences. 2022-11-01. PMID:36318403. |
in short, age at initiation, duration and rate of cannabis use, abstinence duration, co-use of substances and alcohol, prescribed medications, relative cannabinoid composition and potency of cannabis, presence of genetic and environmental vulnerability factors are prominent contributors to the variability in outcomes. |
2022-11-01 |
2023-08-14 |
human |
| Christopher N Andrews, Renata Rehak, Matthew Woo, Ian Walker, Christopher Ma, Nauzer Forbes, Katherine Rittenbach, Joshua Hathaway, Lynn Wilsack, Andy Liu, Yasmin Nasser, Keith A Sharke. Cannabinoid hyperemesis syndrome in North America: evaluation of health burden and treatment prevalence. Alimentary pharmacology & therapeutics. 2022-10-28. PMID:36307209. |
cannabinoid hyperemesis syndrome (chs) is a poorly understood vomiting disorder associated with chronic cannabis use. |
2022-10-28 |
2023-08-14 |
Not clear |
| Justin Matheson, Zoe Bourgault, Bernard Le Fol. Sex Differences in the Neuropsychiatric Effects and Pharmacokinetics of Cannabidiol: A Scoping Review. Biomolecules. vol 12. issue 10. 2022-10-27. PMID:36291671. |
cannabidiol (cbd) is a non-intoxicating cannabinoid compound with diverse molecular targets and potential therapeutic effects, including effects relevant to the treatment of psychiatric disorders. |
2022-10-27 |
2023-08-14 |
human |
| Viktoriia Cherkasova, Bo Wang, Marta Gerasymchuk, Anna Fiselier, Olga Kovalchuk, Igor Kovalchu. Use of Cannabis and Cannabinoids for Treatment of Cancer. Cancers. vol 14. issue 20. 2022-10-27. PMID:36291926. |
use of cannabis and cannabinoids for treatment of cancer. |
2022-10-27 |
2023-08-14 |
Not clear |
| Daniele Lana, Elisa Landucci, Costanza Mazzantini, Giada Magni, Domenico Edoardo Pellegrini-Giampietro, Maria Grazia Giovannin. The Protective Effect of CBD in a Model of In Vitro Ischemia May Be Mediated by Agonism on TRPV2 Channel and Microglia Activation. International journal of molecular sciences. vol 23. issue 20. 2022-10-27. PMID:36292998. |
these different effects of cannabinoid observed in our experiments caution against the indiscriminate use of cannabis or cannabinoid preparations for recreational or therapeutic use. |
2022-10-27 |
2023-08-14 |
rat |
| Ran Abuhasira, Shahar Azar, Alina Nemirovski, Joseph Tam, Victor Novac. Herbal Cannabis Use Is Not Associated with Changes in Levels of Endocannabinoids and Metabolic Profile Alterations among Older Adults. Life (Basel, Switzerland). vol 12. issue 10. 2022-10-27. PMID:36294974. |
there is a scarcity of data on the metabolic effects of exogenous cannabis in older adults; therefore, we aimed to assess the effect of exogenous cannabis on endocannabinoid levels and the association with changes in 24 h ambulatory blood pressure and lipid levels. |
2022-10-27 |
2023-08-14 |
Not clear |
| Ran Abuhasira, Shahar Azar, Alina Nemirovski, Joseph Tam, Victor Novac. Herbal Cannabis Use Is Not Associated with Changes in Levels of Endocannabinoids and Metabolic Profile Alterations among Older Adults. Life (Basel, Switzerland). vol 12. issue 10. 2022-10-27. PMID:36294974. |
on average, cannabis treatment for 3 months does not result in a significant change in the levels of endogenous cannabinoids and thus has a safe metabolic risk profile. |
2022-10-27 |
2023-08-14 |
Not clear |
| Noa Raz, Aharon M Eyal, Elyad M Davidso. Optimal Treatment with Cannabis Extracts Formulations Is Gained via Knowledge of Their Terpene Content and via Enrichment with Specifically Selected Monoterpenes and Monoterpenoids. Molecules (Basel, Switzerland). vol 27. issue 20. 2022-10-27. PMID:36296511. |
cannabinoid and terpene contents were compared between commercial cannabis inflorescences ( |
2022-10-27 |
2023-08-14 |
Not clear |
| Priya Gupta, Archu Singh, Sadat Shafi, Tanya Ralli, Faheem Hyder Pottoo, Kanchan Kohl. Cannabis sativa in Phytotherapy : Reappraisal of therapeutic potential and regulatory aspects. Current pharmaceutical biotechnology. 2022-10-25. PMID:36281862. |
cannabis sativa is widely used as a folk medicine in many parts of the globe and has been reported to be a treasure trove of phytoconstituents, including cannabinoids, terpenoids, and flavonoids. |
2022-10-25 |
2023-08-14 |
Not clear |
| Priya Gupta, Archu Singh, Sadat Shafi, Tanya Ralli, Faheem Hyder Pottoo, Kanchan Kohl. Cannabis sativa in Phytotherapy : Reappraisal of therapeutic potential and regulatory aspects. Current pharmaceutical biotechnology. 2022-10-25. PMID:36281862. |
in the past two decades, extensive research on cannabis has led to the resurgence of interest in the clinical application of its constituents, particularly cannabinoids. |
2022-10-25 |
2023-08-14 |
Not clear |